NCT03638141

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

The Effect of CTLA-4/PD-L1 Blockade Following Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC Using Durvalumab (MEDI4736) and Tremelimumab

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.

Conditions

• Intermediate Stage of Hepatocellular Carcinoma
• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Durvalumab	Durvalumab 1500mg IV every 4 weeks for up to a maximum of 13 cycles (about 12 months) or until confirmed disease progression.
DRUG	Tremelimumab	Tremelimumab 300 mg IV in combination with Durvalumab 1500mg about 2 weeks after their first DEB-TACE.

Timeline

• Start date: 2019-10-02
• Primary completion: 2024-08-20
• Completion: 2024-08-20
• First posted: 2018-08-20
• Last updated: 2025-08-17
• Results posted: 2025-08-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study